BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ekpanyapong S, Philips N, Loza BL, Abt P, Furth EE, Tondon R, Khungar V, Olthoff K, Shaked A, Hoteit MA, Reddy KR. Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience. J Clin Exp Hepatol 2020;10:304-15. [PMID: 32655233 DOI: 10.1016/j.jceh.2019.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Mettikanont P, Kalluri A, Bittermann T, Phillips N, Loza B, Rosen M, Siegelman E, Furth E, Abt P, Olthoff K, Shaked A, Hoteit M, Reddy KR. The Course of LIRADS 3 and 4 Hepatic Abnormalities as Correlated with Explant Pathology: A Single Center Experience. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.02.005] [Reference Citation Analysis]
2 Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Al-Ameri A, Yu X, Zheng S. Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: Systematic review and meta-analysis. Transplant Rev (Orlando) 2021;36:100676. [PMID: 34999555 DOI: 10.1016/j.trre.2021.100676] [Reference Citation Analysis]
4 Zhang XF, Xue F, Bagante F, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Lv Y, Pawlik TM. Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice. J Gastrointest Surg 2021. [PMID: 34797558 DOI: 10.1007/s11605-021-05206-8] [Reference Citation Analysis]
5 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 26.0] [Reference Citation Analysis]
6 Li L, Ji Y, Chen YC, Zhen ZJ. MiR-325-3p mediate the CXCL17/CXCR8 axis to regulate angiogenesis in hepatocellular carcinoma. Cytokine 2021;141:155436. [PMID: 33515898 DOI: 10.1016/j.cyto.2021.155436] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Sugawara Y, Hibi T. Liver transplantation for patients with hepatocellular carcinoma: Its current status and advances. Biosci Trends 2022. [PMID: 35613874 DOI: 10.5582/bst.2022.01199] [Reference Citation Analysis]